Cellphire Therapeutics, Inc. products

Thrombosomes are made by pooling platelet units from 10 Group O (Universal) blood donors, removing the plasma and adding a natural sugar, trehalose, to stabilize the cells. Water is then removed through a freeze-drying process resulting in a dry powder. The dry product is heat treated as a final step to reduce the risk of viral transmission and then tested for the presence of bacteria prior to release for use. The dried platelets are rehydrated in minutes by adding sterile water and are then ready for infusion.

Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes, is an activated platelet-based hemostatic. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. Thrombosomes has also been given orphan drug designation for the treatment of Acute Radiation Sickness by the U.S. Food and Drug Administration.

The basis of Cellphire’s technology is derived from nature. There are plants and animals able to withstand the loss of water caused by severe heat or cold by making the sugar trehalose, which replaces the water that evaporates over time. Once re-exposed to a humid atmosphere or water, they “come back to life” and are fully functional/viable.